Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Calliditas Therapeutics
5 seuraajaa
NäytäKaikki sisältötyypit
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
Redeye: Calliditas Update - The Final Countdown
Calliditas Therapeutics, Audiocast with teleconference, Q2'24
Calliditas Therapeutics: Calliditas Interim Report January to June 2024
Calliditas Therapeutics: Invitation to the presentation of Calliditas's interim report January - June 2024
Number of shares and votes in Calliditas Therapeutics
Calliditas Therapeutics: Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy
Calliditas Therapeutics: Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis
Calliditas Therapeutics: Launch of Phase 3 clinical trial with Nefecon in Japan
Calliditas Therapeutics: Calliditas provides setanaxib patent update
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)
Calliditas Therapeutics: Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo[®] for the treatment of IgA nephropathy
Calliditas Therapeutics R&D Day, 2024
Calliditas Therapeutics Presents Data at the 61[st] European Renal Association Congress
Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation
Redeye: Calliditas Q1 - Powerful launch momentum
